Understanding itch: An update on mediators and mechanisms of pruritus

Indian Journal of Dermatology, Venereology and Leprology

Volumn 80, Issue 2, 2014, Pages 106-114

  Hassan, Iffat ^a   Haji, Mir Laieq ^a  

^a UNIVERSITY OF KASHMIR   (India)

Author keywords

Itch; mediators; neural pathways; pathophysiology; pruritus

Indexed keywords

ACETYLCHOLINE; CALCITONIN GENE RELATED PEPTIDE; CANNABINOID; CANNABINOID RECEPTOR; CORTICOTROPIN RELEASING FACTOR; ENDOCANNABINOID; GAMMA INTERFERON; HISTAMINE; INTERLEUKIN 31; INTERLEUKIN 6; NERVE GROWTH FACTOR; NEUROTROPHIN; OPIATE PEPTIDE; PROSTAGLANDIN; PROTEINASE; SEROTONIN; SUBSTANCE P; TRANSIENT RECEPTOR POTENTIAL CHANNEL;

CELL LABELING; CELL SPECIFICITY; HUMAN; NERVE FIBER; NERVE POTENTIAL; NERVE TRACT; NONHUMAN; PATHOPHYSIOLOGY; PRURITUS; REVIEW; SPINAL CORD NERVE CELL; INNERVATION; METABOLISM; NONMYELINATED NERVE; SKIN; SKIN DISEASES;

HUMANS; NERVE FIBERS, UNMYELINATED; PRURITUS; SKIN; SKIN DISEASES;

EID: 84897534649     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.129377     Document Type: Review

References (121)

1. Hafenreffer S. Nosodochium, in quo cutis, eique adaerentium partium, affectusomnes, singulari methodo, et cognoscendi e curandi fidelisime traduntur. Ulmae(Westphalia) Kühnen; 1660. p. 98-102
2. Rothman S. Physiology of itching. Physiol Rev1941;21:357-81.
3. Savin J. How should we define itching? J Am Acad Dermatol1998;39:268-9.
4. Yosipovitch G, Greaves MW. Definitions of itch. In: Yosipovitch G, Greaves MW, Fleischer AB, McGlone F, editors. Itch: Basic mechanisms and therapy. New York: Marcel Dekker; 2004. p. 1.
5. Steinhoff M, Bienenstock J, Schmelz M, Maurer M, Wei E, Biro T. Neurophysiological, neuroimmunological, and neuroendocrine basis of pruritus. J Invest Dermatol 2006;126:1705-18.
6. Kini SP, DeLong LK, Veledar E, McKenzie-Brown AM, Schaufele M, Chen SC. The impact of pruritus on quality of life: The skin equivalent of pain. Arch Dermatol 2011;147:1153-6.
7. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE Szepietowski JC, et al. Itch: Scratching more than the surface. Q J Med 2003; 96:7-26.
8. Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. Theneurobiology of itch. Nat Rev Neurosci 2006;7:535-47.
9. Tuckett RP. Itch evoked by electrical stimulation of the skin. J Invest Dermatol 1982;79: 368-73.
10. Schmelz M, Schmidt R, Bickel A, Handwerker HO, Torebjork HE. Specific C-receptors for itch in human skin. J Neurosci 1997;17:8003-8.
11. Patel KN, Dong X. Itch: Cells, molecules, and circuits. ACS Chem Neurosci 2011;2:17-25.
12. Andrew D, Craig AD.Spinothalamic lamina I neurons selectively sensitive to histamine: A central neural pathway for itch.Nat Neurosci 2001;4:72.
13. Simone DA, Zhang X, Li J, Zhang JM, Honda CN, LaMotte RH, et al. Comparison of responses of primate spinothalamic neurons to pruritic and algogenic stimuli. J Neurophysiol 2004;91:213-22.
14. Schmelz M, Schmidt R, Weidner C, Hilliges M, Torebjork HE, Handwerker HO.Chemical responsepatternofdifferentclasses of C-nociceptorstopruritogens and algogens. J Neurophysiol 2003;89:2441-8.
15. Davidson S, Zhang X, Yoon CH, Khasabov SG, Simone DA, Giesler GJ Jr.The itch-producing agents histamine and cowhage activate separate populations of primate spinothalamic tract neurons. J Neurosci 2007;27:10007-14.
16. Namer B, Carr R, Johanek LM, Schmelz M, Handwerker HO, Ringkamp M. Separate peripheral pathways for pruritus in man.J Neurophysiol 2008;100:2062-9.
17. Johanek LM, Meyer RA, Hartke T, Hobelmann JG, Maine DN, LaMotte RH, et al.Psychophysical and physiological evidence for parallel afferent pathways mediating the sensation of itch. J Neurosci 2007;27:7490-7.
18. Reddy VB, Luga AO, Shimada SG, LaMotte RH, Lerner EA. Cowhage-evoked itch is mediated by a novel cysteine protease: A ligand of protease-activated receptors. J Neurosci 2008;28:4331-5.
19. Papoiu AD, Tey HL, Coghill RC, Wang H, Yosipovitch G. Cowhage-Induced Itch as an Experimental Model for Pruritus. A Comparative Study with Histamine-Induced Itch.PLoS One 2013;6:e17786.
20. Steinhoff M, Neisius U, Ikoma A, Fartasch M, Heyer G, Skov PS, et al. Proteinase-activated receptor-2 mediates itch: A novel pathway for pruritus in human skin. J Neurosci 2003;23:6176-80.
21. Liu T, Xu ZZ, Park CK, Berta T, Ji RR. Toll-like receptor 7 mediatespruritus. Nat Neurosci 2010;13:1460-2.
22. Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007;448:700-3.
23. Sun YG, Zhao ZQ, Meng XL, Jun Y, Yu XL, Feng CZ. Cellular basis of itchsensation. Science 2009;325:1531-4.
24. Yosipovitch G, Greaves M, Schmelz M. Itch. Lancet 2003;36:690-4.
25. Hsieh JC, Hägermark O, Ståhle-Bäckdahl M, Ericson K, Eriksson L, Stone-Elander S, et al. Urge to scratch represented in the human cerebral cortex during itch. J Neurophysiol1994;72:3004-38.
26. Darsow U, Drzezega A, Frisch M, Munz F, Weilke F, Bartenstein P, et al. Processing of histamine induced itch in the human cerebral cortex: A correlation analysis withdermal reactions. J Invest Dermatol 2000;115:1029-33.
27. Drzezga A, Darsow U, Treede RD, Siebner H, Frisch M, Munz F, et al. Central activation by histamine-induced itch: Analogies to pain processing: A correlationalanalysis of O-15 H2O positron emission tomography studies. Pain 2001;92:295-305.
28. Mochizuki H, Tashiro M, Kano M, Sakurada Y, Itoh M, Yanai K. Imaging of central itch modulation in the human brain using positron emission tomography. Pain 2003;105:339-46.
29. Ghez C. Voluntary movement. In: Kandel ER, Schwartz JH, editors. Principles of Neural Science. 2 nd ed. New York, NY: Elsevier; 1985:756-81
30. Yosipovitch G, Papoiu A DP.Cutaneous Neurophysiology. In: Bolognia JL, Jorizzo JL, Schaffer JV, editors.Dermatology. 3 rd ed. New York: Elsevier; 2012:99-109.
31. Han SK, Mancino V, Simon MI.Phospholipase Cβ 3 mediates the scratching response activated by the histamine H1 receptor on C-fiber nociceptive neurons. Neuron 2006;52:691-703.
32. Huang JF, Thurmond R. The new biology of histamine receptors. Curr Allergy AsthmaRep 2008;8:21-7.
33. Dunford PJ, O'Donnell N, Riley JP, Williams KN, Karlsson L, Thurmond RL, et al. The histamine H 4 receptor mediates allergic airway inflammation by regulating the activation of CD4+T cells. J Immunol 2006;176:7062-70.
34. Bell JK, McQueen DS, Rees JL.Involvement of histamine H 4 and H 1 receptors in scratching induced by histamine receptor agonists in BalbC mice. Br J Pharmacol 2004;142:374-80.
35. Cowden JM, Zhang M, Dunford PJ, Thurmond RL. The Histamine H 4 Receptor Mediates Inflammation and Pruritus in Th2-Dependent Dermal Inflammation.J Investig Dermatol 2010;130:1023-33.
36. MiyamotoT, Nojima H, Kuraishi Y. Intradermalcholinergic agonists induce itch-associated responsevia M3 muscarinic acetylcholine receptors in mice. Jpn JPharmacol 2002;88:351-4.
37. Heyer GR, Hornstein OP. Recent studies of cutaneous nociception in atopic and non-atopic subjects. J Dermatol 1999;26:77-86.
38. Rukwied R, Lischetzki G, McGlone F, Heyer G, Schmelz M. Mast cell mediators other than histamine induce pruritus in atopic dermatitis: A dermal microdialysis study. Br J Dermatol 2000;142:1-8.
39. Ikoma A.Updated Neurophysiology of Itch. Biol Pharm Bull 2013;36:1235-40.
40. Hansson L, Backman A, Ny A, Edlund M, Ekholm E, Ekstrand Hammarström B, et al. Epidermal overexpression of stratum corneum chymotryptic enzyme in mice: A model for chronic itchy dermatitis. J Invest Dermatol 2002;118:444-9.
41. Steinhoff M, Vergnolle N, Young SH, Tognetto M, Amadesi S, Ennes HS, et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000;6:151-8.
42. Cormia FE, Dougherty JW. Proteolytic activity in development of pain anditching: Cutaneous reactions to bradykinin and kallikrein. J Invest Dermatol1960;35:21-6.
43. Hägermark O. Itch mediators. Semin Dermatol 1995;14:271-6.
44. Wallengren J, Hakanson R. Effects of substance P, neurokinin A and calcitonin gene-related peptide in humanskin and their involvement in sensory nerve-mediated responses. Eur J Pharmacol 1987;143:267-73.
45. Ny A, Egelrud T. Epidermal hyperproliferation and decreased skin barrier function in mice overexpressing stratum corneum chymotryptic enzyme Acta Dermatol Venereol 2004;84:18-22.
46. Hayashi I, Majima M. Reduction of sodium deoxycholicacid-induced scratching behaviour by bradykinin B2 receptor antagonists. Br J Pharmacol 1999;126:197-204.
47. Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. JAMA 1987;258:1624-9.
48. Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997;137:415-7.
49. Dillon SR, Sprecher C, Hammond A, Bilsborough J, Rosenfield-Franklin M, Presnell SR, et al. Interleukin 31, a cytokine producedby activated T cells, induces dermatitis in mice. Nat Immunol 2004;5:752-60.
50. Grimstad O, Sawanobori Y, Vestergaard C, Bilsborough J, Olsen UB, Grønhøj-Larsen C, et al. Anti-interleukin-31-antibodies ameliorate scratching behaviour in NC/Nga mice: A model of atopic dermatitis. Exp Dermatol 2009;18:35-43.
51. Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L, et al. IL-31: A new linkbetween T cells and pruritus in atopic skininflammation. J Allergy Clin Immunol 2006;117:411-7.
52. Neis MM, Peters B, Dreuw A, Wenzel J, Bieber T, Mauch C, et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006;118:930-7.
53. Nordlind K, Chin LB, Ahmed AA, Brakenhoff J, Theodorssson E, Liden S.Immunohistochemical localization of interleukin-6-likeimmunoreactivity to peripheral nerve-like structures innormal and inflamed human skin. Arch Dermatol Res1996;288:431-5.
54. Chan LS, Robinson N, Xu L. Expression of interleukin-4 in the epidermis oftransgenic mice results in a pruritic inflammatory skin disease: An experimental animal model to study atopic dermatitis. J Invest Dermatol 2001;117:977-83.
55. Jorizzo JL, Coutts A, Greaves MW. Vascular responses of human skin to injection of substance P and mechanism of action. Eur J Pharmacol 1983;87:67-76.
56. Toyoda M, Nakamura M, Makino T, Hino T, Kaqoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers ofdisease activity in atopic dermatitis. Br J Dermatol 2002;147:71-9.
57. Schmelz M, Zeck S, Raithel M, Rukwied R. Mast celltryptase in dermal neurogenic inflammation. Clin ExpAllergy 1999;29:695-702.
58. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, et al. Acute effects ofsubstance P and calcitonin gene-related peptide in humanskin: A microdialysis study. J Invest Dermatol 2000;115:1015-20.
59. Suzuki R, Furuno T, McKay DM, Wolvers D, Tashima R, Nakanishi M, et al. Direct neurite-mast cell communicationin vitro occurs via the neuropeptide substance P. J Immunol1999;163:2410-5.
60. Shanahan F, Denburg JA, Fox J, Bienenstock J, Befus D. Mast cell heterogeneity: Effects of neuroentericpeptides on histamine release. J Immunol1985;135:1331-7.
61. Cocchiara R, Lampiasi N, Albeggiani G, Bongiovanni A, Azzolina A, Geraci D. Mast cellproduction of TNF-alpha induced by substance Pevidence for a modulatory role of substanceP-antagonists. J Neuroimmunol 1999;101:128-36.
62. Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin inhumans: Parallel loss of epidermal nerve fibres and painsensation. Pain 1999;81:135-45.
63. Costa SK, Starr A, Hyslop S, Gilmore D, Bran SD. How importantare NK1 receptors for influencing microvascular inflammation and itch in the skin? Studies using Phoneutria nigriventorvenom.Vascul Pharmacol 2006;45:209-14.
64. Duval A, Dubertret L. Aprepitant as an antipruritic agent? N Engl J Med 2009;361:1415-6.
65. Heyer G, Dotzer M, Diepgen TL, Handwerker HO. Opiateand H1 antagonist effects on histamine inducedpruritus and alloknesis. Pain 1997;73:239-43.
66. Blunk JA, Schmelz M, Zeck S, Skov P, Likar R, Koppert WOpioid-inducedmastcell activation and vascular responses is not mediated by μ-opioid receptors: An in vivomicrodialysisstudyinhumanskin. Anesth Analg 2004;98:364-70.
67. Onigbogi O, Ajayi AA, Ukponmwan OE. Mechanisms of chloroquine-inducedbody scratchingbehaviorinrats: Evidenceof involvement of endogenous opioid peptides. Pharmacol Biochem Behav 2000;65:333-7.
68. Saiah M, Borgeat A, Wilder-Smith OH, Rifat K, Suter PM.Epidural morphine induced pruritus: Propofol vs naloxone. Anesth Analg 1994;78:1110-3.
69. Krause L, Shuster S.Mechanism of action of anti pruritic drugs.Br Med J (Clin Res Ed) 1983;287:1199-200.
70. Umeuchi H, Togashi Y, Honda T, Nakao K, Okano K, Tanaka T, et al. Involvement ofcentral mu-opioid system in the scratching behavior inmice and the suppression of it by the activation ofkappa-opioid system. Eur J Pharmacol 2003;477:29-35.
71. Peer G, Kivity S, Agami O, Fireman E, Silverberg D, Blum M, et al. Randomised crossover trial of naltrexone in uraemic pruritus.Lancet 1996;348:1552-4.
72. Bergasa NV. The pruritus of cholestasis. J Hepatol 2005;43:1078-88.
73. Kumagai H, Ebata T, Takamori K, Muramatsu T, Nakamoto H, Suzuki H. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: A Phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant2010;25:1251-7.
74. Ständer S, Moormann C, Schumacher M, Buddenkotte J, Artuc M, Shpacovitch V, et al. Expression of vanilloid receptor subtype 1 in cutaneous sensory nerve fibers, mast cells, and epithelial cells of appendagestructures. Exp Dermatol 2004;13:129-39.
75. Paus R, Schmelz M, Bíró T, Steinhoff M.Frontiers in pruritus research: Scratching the brain for more effective itch therapy. J Clin Invest2006;116:1174-85.
76. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, TrevisaniM, et al. Protease-activated receptor 2 sensitizes the capsaicin receptortransientreceptorpotentialvanilloidreceptor1to inducehyperalgesia. J Neurosci 2004;24:4300-12.
77. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, Travers JB. Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes.J Pharmacol Exp Ther 2003;304:217-22.
78. Peier AM, Reeve AJ, Andersson DA, Moqrich A, Earley TJ, Hergarden AC, et al. Aheat-sensitive TRP channel expressed inkeratinocytes. Science 2002;296:2046-9.
79. Smith GD, Gunthorpe MJ, Kelsell RE, Heyes PD, Reilly P, Facer P, et al.TRPV3 is a temperaturesensitivevanilloid receptor-like protein. Nature2002;418:186-90.
80. Watanabe H, Vriens J, Prenen J, Droogmans G, Voets T, Nilius B. Anandamide and arachidonic acid use epoxyeicosatrienoic acids toactivate TRPV4 channels. Nature 2003;424:434-8.
81. Stokes AJ, Shimoda LM, Koblan-Huberson M, Adra CN, Turner H. A TRPV2-PKAsignaling module for transduction of physicalstimuli in mast cells. J Exp Med 2004;200:137-47.
82. McKemy DD, Neuhausser WM, Julius D.Identification of a cold receptor reveals ageneral role for TRP channels in thermosensation.Nature2002;416:52-8.
83. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, et al. ATRP channel that senses cold stimuli andmenthol. Cell 2002;108:705-15.
84. Biro T, Ko MC, Bromm B, Wie ET, Bigliardi P, Siebenhaar F, et al. How best to fight that nastyitch from new insights into the neuroimmunological, neuroendocrine, and neurophysiologicalbases of pruritus to novel therapeutic approaches.ExpDermatol2005;14:225-40.
85. Wilson SR, Gerhold KA, Bifolck-Fisher A, Liu Q, Patel KN, Dong X, et al. TRPA1 isrequired for histamine-independent, Mas-related Gprotein-coupled receptor-mediated itch. Nat Neurosci2011;14:595-602.
86. Hagermark O, Strandberg K. Pruritogenic activity ofprostaglandin E2. Acta Derm Venereol 1977;57:37-43.
87. Lovell CR, Burton PA, Duncan EH, Burton JL. Prostaglandins and pruritus. Br J Dermatol 1976;94:273-5.
88. Daly BM, Shuster S. Effect of aspirin on pruritus. BMJ 1986;293:907.
89. Jackson N, Burt D, Crocker J, Boughton B. Skin mastcells in polycythaemia vera: Relationship to the pathogenesis and treatment of pruritus. Br J Dermatol 1987;116:21-9.
90. Yosipovitch G, Sugeng MW, Chan YH, Goon A, Ngim S, Goh CL. The effect of topically applied aspirinon localized circumscribed neurodermatitis. J Am Acad Dermatol2001;45:910-3.
91. Smith KJ, Skelton HG, Yeager J. Pruritus in HIV-1 disease: Therapy with drugs which may modulate thepattern of immune dysregulation. Dermatology 1997;195:353-8.
92. Colbert S, O'Hanlon DM, Galvin S, Chambers F, Moriarty DC. The effect of rectal diclofenac on pruritusin patients receiving intrathecal morphine. Anaesthesia 1999;54:948-52.
93. Anhoh T, Nishikawa Y, Yamaguchi-Myamoto T, Nojima H, Narumiya S, Kuraiushi Y. Thromboxane A2 inducesitch-associated responses through TP receptors in the skin in mice. J Invest Dermatol 2007;127:2042-7.
94. Andoh T, Yageta Y, Takeshima H, Kuraishi Y. Intradermalnociceptin elicits itch-associated responses throughleukotriene B(4) in mice. J Invest Dermatol 2004;123:196-201.
95. Johansson O, Liang Y, Emtestam L. Increased nerve growth factor-and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin: An exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002;293:614-9.
96. Aloe L. Rita Levi-Montalcini: The discoveryof nerve growth factor and modern neurobiology.Trends Cell Biol2004;14:395-9.
97. Groneberg DA, Serowka F, Peckenschneider N, Artuc M, Grutzkau A, Fischer A, et al. Gene expression and regulation of nervegrowth factor in atopic dermatitis mast cellsand the human mast cell line-1. J Neuroimmunol2005;161:87- 92.
98. Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity inatopic dermatitis. Br J Dermatol 2002;147:71-9.
99. Grewe M, Vogelsang K, Ruzicka T, Stege H, Krutmann J. Neurotrophin-4 production by human epidermal keratinocytes: Increased expression in atopic dermatitis. J Invest Dermatol 2000;114:1108-12.
100. Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by cannabinoid receptor agonist in human skin. Inflamm Res 2003;52:238-45.
101. Van der Stelt M, Trevisani M, Vellanni V, Petrocellis LD, Moriello AS, Campi B, et al.Anandamide acts as anintracellular messenger amplifying Ca(2+) influx via TRPV1 channels. EMBO J 2005;24:3517-8.
102. Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor antagonist reduce experimentally-induced itch? Inflamm Res 1997;46:412-6.
103. Weisshaar E, Ziethen B, Rohl FW, Gollnick H. Theantipruritic effect of a 5HT3 receptor antagonist (tropisetron) is dependent on mast cell depletion: An experimental study. Exp Dermatol 1999;8:254-60.
104. Borgeat A, Stimemann HR. Ondansetron is effective totreat spinal or epidural morphine-induced pruritus. Anesthesiology 1999;90:432-6.
105. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomized, placebo-controlleddouble-blind trial of ondansetron in renal itch. Br J Dermatol 2003;148:314-7.
106. Brain SD, Grant AD. Vascularactionsof calcitonin gene-related peptide and adrenomedullin. Physiol Rev 2004;84:903-34.
107. Ekblom A, Lundeberg T, Wahlgren CF. Influence of calcitonin gene-related peptide on histamine-and substance P-induced itch, flare and weal in humans. SkinPharmacol 1993;6:215-22.
108. Jarvikallio A, Harvima IT, Naukkarinen A. Mast cells, nerves and neuropeptides in atopic dermatitis and nummular eczema. Arch Dermatol Res 2003;295:2-7.
109. Liang Y, Jacobi HH, Reimert CM, Haak-Frendscho M, Marcusson JA, Johansson O. CGRP-immunoreactive nerves in prurigo nodularis: An exploration ofneurogenic inflammation. J Cutan Pathol 2000;27:359-66.
110. Weidner C, Klede M, Rukwied R, Lischetzki G, Neisius U, Skov PS, et al. Acute effects of substance P and calcitonin gene-related peptide in human skin-a microdialysisstudy. J Invest Dermatol 2000;115:1015-20.
111. Theoharides TC, Singh LK, Boucher W, Pang X, Letourneau R, Webster E, et al. Corticotropin-releasing hormone induces skin mast cell degranulation and increased vascular permeability, a possible explanation for its proinflammatory effects. Endocrinology 1998;139:403-13.
112. Cao J, Papadopoulou N, Kempuraj D, Boucher WS, Sugimoto K, Cetrulo CL, et al. Humanmast cells express corticotropin releasing hormone (CRH) receptors and CRH leads to selective secretion of vascular endothelial growth factor.J Immunol 2005;174:7665-75.
113. Singh LK, Pang X, Alexacos N, Letourneau R, Theoharides TC. Acute immobilization stress triggers skin mast cell degranulation via corticotropin releasing hormone, neurotensin, and substance P: A link to neurogenic skin disorders. Brain Behav Immun 1999;13:225-39.
114. Andoh T, Yageta Y, Takeshima H, Kuraishi Y. Intradermal nociceptin elicits itch-associated responses throughleukotriene B(4) in mice. J Invest Dermatol 2004;123:196-201.
115. Zabawski EJ Jr, Kahn MA, Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999;5:10.
116. Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol. 1999;83:548-52.
117. Rukwied R, Heyer G. Cutaneous reactions and sensations after intracutaneous injection of vasoactive intestinal polypeptide and acetylcholine in atopic eczema patients and healthy controls. Arch Dermatol Res 1998;290:198-204.
118. Church MK, el-Lati S, Caulfield JP. Neuropeptide-induced secretion from human skin mast cells. Int Arch Allergy Appl Immunol 1991;94:310-8.
119. Andoh T, Kuraishi Y. Nitric oxide enhances substanceP-induced itch-associated responses in mice. Br JPharmacol 2003;138:202-8.
120. Gmerek DE, Cowan A. Bombesin: A central mediator of pruritus? Br J Dermatol 1983;109:239.
121. Gmerek DE, Cowan A. An animal model for preclinical screening of systemic antipruritic agents.J Pharmacol Methods 1983;10:107-12.